|CCL 06.06.04 Applying Mechanisms of Chemical Toxicity to Predict Drug Safety, WASHINGTON, D.C|
From: chemistry-request at ccl.net
To: chemistry-request at ccl.net
Date: Wed Feb 1 09:50:19 2006
Subject: 06.06.04 Applying Mechanisms of Chemical Toxicity to Predict Drug Safety, WASHINGTON, D.C
Applying Mechanisms of Chemical Toxicity to Predict Drug Safety JUNE 4 6, 2006 | OMNI SHOREHAM | WASHINGTON, D.C. http://www.chemistry.org/portal/a/c/s/1/acsdisplay.html?DOC=acsprospectives%5c06toxicity%5cindex.html Today, pharma discovery scientists have the benefit of excellent chemistry and often a wealth of drug candidates to choose from. Many, if not most drug candidates fail due to toxicology issues, so chairs Prof. F. Peter Guengerich, Professor of Biochemistry and t he Director of Vanderbilts Center in Molecular Toxicology, and Dr. James MacDonald, EVP of Preclinical Development at the Schering-Plough Research Institute, specifically organized this conference to aid industry scientists in the early prediction of which candidates will prove toxic. The conference will discuss basic and practical issues of chemical tox as well as newer technologies. It will also cover what systems have proven most useful in prediction, and how information can be best used in the regulatory process. The sessions are designed to encourage discussion and audience participation and are arranged around the topics of: Mechanisms of Chemically Induced Toxicity: * Prof. Sidney Nelson of the University of Washington will speak on structural alerts in medicinal chemistry and the science of reactive metabolites * Prof. Timothy Macdonald of the University of Virginia will speak on felbamate and other problem drugs and the roles that reactive metabolites play in toxicity * Dr. David Evans of Johnson & Johnson will speak on the application of covalent binding screening and its usefulness in decisions * Dr. David Thompson of Pfizer will speak on contexts of drug toxicity and the extents of contribution of major mechanisms including reactive metabolites, off-target toxicity, on-target toxicity, and immune reaction Celluar Responses to Chemically Induced Toxicity: * Prof. Christopher Bradfield of the University of Wisconsin will speak on studies with the AhR receptor and genomic and informatic approaches to understanding its roles * Prof. Thomas Kensler of Johns Hopkins University will speak on the Keap1/Nrf2 system in a model of regulation of pathways by toxicant reactions * Dr. S. G. Rhee of NIH will speak on redox linked regulatory systems, including the peridoxins, and their roles as mediators of response to toxic injury * Dr. Donald Nicholson of Merck will discuss the role of apoptosis in cell injury Potential Molecular & In Vitro Approaches to the Detection of Cellular Responses: * Lois Lehman-McKeeman of BMS will speak on new technologies that are impacting decisions in discovery toxicology and overall strategies for new technology applications. * Tim Ryan of Eli Lilly will present case studies illustrating the application of genomic technology to safety assessment. * Cindy Afshari of Amgen will present case studies on combining in vitro models with new technology in early safety screening, and safety assessment of bioproducts. * Don Robertson of Pfizer will present case studies illustrating the use of metabonomics as an early safety assessment tool. * Dr. James Stevens of Eli Lilly, a leader in the area of molecular toxicology, will chair this session. The Status of Molecular Approaches (Whats Working, Whats Yet to Be Done): * David Jacobsen-Kramm of the FDA Office of Pharmacology and Toxicology will speak on the agencys efforts to understand how to best utilize technologies to predict potential human risk * Bruce Carr of BMS will speak on identifying signals of potential concern for human tox in drug candidates * Michael Cunningham of NIEHS will speak on exploring how effects of chemicals on various organ systems can be detected with molecular tools at doses that are not associated with frank toxicity * Eric Bloome of Abbott will speak on molecular/in vitro approaches to assessing potential chemical induced toxicity in a drug development environment. Keynote: * Prof. Gilbert Omenn of the University of Michigan and current President of the American Association for the Advancement of Science (AAAS) will speak on the promise and challenge of accurately predicting potential human risk. Short Course (optional): * Roger Ulrich of Merck/Rosetta will give an overview of genomics and small RNA interference, Prof. Daniel Liebler of Vanderbilt University will give an overview on proteomics and metabolomics. An FDA perspective is also planned, with the speaker TBD.NOTE THAT E-MAIL ADDRESSES HAVE BEEN MODIFIED!!!
All @ signs were changed to !A! to fight spam. Before you send e-mail, you need to change !A! to @
For example: change joe!A!big123comp.com to firstname.lastname@example.org
Please let colleagues know about conference listingts at Computational Chemistry List Conference Page at http://www.ccl.net/chemistry/a/conferences/.
Please help: If you find this conference list useful but you noticed some conference missing, please consider including it here by using the Conference Submission Page. It is free but your support is welcome. You will help others!!!
|Modified: Wed Feb 1 14:50:19 2006 GMT|
|Page accessed 5012 times since Wed Feb 1 14:50:19 2006 GMT|
Please help maintain CCL: If you found that your conference is listed here, please consider supporting CCL as a Supporting Member or use other Paid Services of CCL to ensure the continuation of this useful service. We cannot do it without your help.